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Abstract
Objective: To determine whether there are differences in 
clinical response after radiotherapy and 1 year survival in 
patients with advanced cervical cancer with and without 
enlargement of PALN.
Methods: An observational analytic study using a 
retrospective cohort method was done using consecutive 
sampling. The subjects of this study were all women with 
a primary diagnosis of stages IIB to IVB cervical cancer 
who came to the gynecological oncology clinic of Dr. Cipto 
Mangunkusumo National General Hospital and underwent 
MRI examination before undergoing treatment in January 
2016 to May 2017.
Results: Among 76 subjects studied, there were 4 (5.1%) 
subjects who had enlarged PALN. There were no signifi cant 
differences between the enlargement status of PALN and 
age (p = 0.829), age of fi rst sexual intercourse (p = 0.33), 
parity (p = 0.642), mass diameter (p = 0.777). Patients with 
PALN enlargement have 2.13 times risk of having negative 
radiotherapy outcome (p = 0.02, OR 2.13, CI95% 1.12 – 4.07). 
There was no difference in 1-year survival between patients 
with and without enlargement of PALN (median 201 vs. 293, 
p = 0.072).
Conclusions: Patients with PALN enlargement have 
increased risk of having negative radiotherapy outcome (p 
< 0.05). There were no differences in 1 year survival between 
patients with advanced cervical cancer with enlargement 
PALN.
Keywords: cervical cancer, lymph node enlargement, 
paraaortic, radiotherapy.
Abstrak
Tujuan: Mengetahui adakah perbedaan respon klinis pas-
caradioterapi dan kesintasan 1 tahun pada pasien kanker 
serviks stadium lanjut dengan pembesaran KGB paraaorta 
dibandingkan tanpa pembesaran KGB paraaorta.
Metode: Penelitian ini merupakan penelitian analitik 
observasional dengan menggunakan metode kohort 
retrospektif. Pengambilan sampel dilakukan dengan cara 
pengambilan sampel berturut-turut. Subyek penelitian ini 
adalah semua perempuan dengan diagnosis primer kanker 
serviks stadium IIB hingga IVB yang datang ke poliklinik 
Onkologi Ginekologi RSUPN Dr. Cipto Mangunkusumo dan 
menjalani pemeriksaan MRI sebelum dilakukan terapi pada 
bulan Januari 2016 hingga Mei 2017.
Hasil: Dari 76 subjek yang diteliti, didapatkan sebanyak 4 
(5,1%) subyek yang mengalami pembesaran KGB paraaorta. 
Tidak didapatkan perbedaan yang bermakna antara status 
pembesaran KGB paraaorta dan usia (p = 0,829), usia 
hubungan seksual pertama (p = 0,333), paritas (p = 0,642), 
dan diameter massa (p = 0,777). Pasien dengan pembesaran 
KGB paraaorta memiliki risiko 2,13 kali lipat (p = 0,02, OR 
2,13, IK95% 1,12-4,07) memiliki risiko respon terapi negatif. 
Tidak terdapat perbedaan kesintasan 1 tahun antara 
pembesaran KGB paraaorta dan tidak (median 201 vs. 293, 
p = 0,072).
Kesimpulan: Pasien dengan pembesaran KGB paraaorta 
memiliki risiko lebih tinggi mengalami respon radioterapi 
negatif. (p < 0,05). Tidak terdapat kesintasan 1 tahun an-
tara pasien kanker serviks stadium lanjut dengan dan tanpa 
pembesaran KGB.
Kata kunci: kanker serviks,  paraaorta,  pembesaran KGB, 
radioterapi.
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INTRODUCTION
Cervical cancer is the third leading cause of 
morbidity and mortality in women worldwide1-3. 
GLOBOCAN survey results in 2018 showed that 
569,847 women diagnosed with cervical cancer 
with new cases with a mortality rate of 311,365 
worldwide2. The Ministry of Health of the Republic 
of Indonesia estimates that the incidence of 
cervical cancer is 100 / 100,000 women per year 
and ranks second in the ranking of cancer cases 
in Indonesian women.3 Previous study data in 
2007 stated that 75% of gynecological cancers 
originated from the cervix, and more than 50% 
of which were diagnosed with advanced stage3. 
This data shows that cervical cancer needs to be 
highlighted as one of the female main causes of 
fatalities in Indonesia4.
Determination of staging in cervical cancer is 
very important because it is very infl uential, not 
only on its management but also on the patient's 
prognosis5,6. Life expectancy will decrease as 
the stage increases of which cervical cancer 
is diagnosed. The development of medical 
technology in recent decades, especially imaging 
technology, created a paradigm of imaging 
technology as a vital part of cancer management. 
In 2018, FIGO had revised its guidelines of cervical 
cancer, recommending imaging modalities as an 
additional examination to further guide clinician 
in diagnosis and treatment choice7,8.
Along with time advancement and the 
development of various medical diagnostic 
tools, there are some addition of new categories 
in the FIGO scoring system, namely in stage 3C 
which is now separated into 3C1 and 3C2. Stage 
3C states that metastasis has occurred to pelvic 
and/or paraaortic lymph nodes, whereas at stage 
3C1 there is only pelvic metastasis and stage 3C2 
metastasis has occurred to the paraaortic lymph 
nodes8. In patients without metastasis to lymph 
nodes, the 5-year overall survival rate (5-YSR) 
is about 85-90%. However, when metastases 
to lymph nodes are obtained, 5-YSR decreases 
between 20-75%.8
Although it is known that enlargement of 
paraaortic lymph nodes has a worse effect on 
patient outcomes, there has never been a study 
in Indonesia on how worse the effects exerted on 
the radiotherapy response and overall survival. 
Therefore, this study seeks to provide an overview 
of the effect of paraaortic enlarged lymph nodes 
on the success of therapy and patient survival.
METHODS
Analytic observational research with 
retrospective cohort method was done in 
Gynecologic Oncology clinic in National General 
Hospital Dr. Cipto Mangunkusumo, Jakarta, 
Indonesia on March 2018 to June 2019. The study 
population were women diagnosed with primary 
cervical cancer stage IIIB to IVB, undergoing 
magnetic resonance imaging (MRI) before and 
after treatment, and completed treatment with 
radiotherapy. Patients with another malignancy 
or having incomplete medical record were 
excluded in this study. 
Consecutive sampling method was done 
in this study. Patients were then divided into 
paraaortic lymph node (PALN) enlargement 
group and control group. PALN enlargement 
was determined using MRI and examined by 
radiology consultant. Baseline characteristics 
were then analyzed and compared. Bivariate 
analysis between subjects’ characteristics and was 
done. Survival analysis using Kaplan-Meier was 
done to all subjects and overall survival between 
study groups were compared. Ethical clearance 
was issued from health research and ethical 




During the time of the study, a total of 118 
subjects were recruited. However, 39 patients 
met the exclusion criteria and were excluded 
from the study. Among 79 patients included in 
this study, 1 patient did not come for follow up 
after treatment. Among 78 subjects of this study, 
4 patients was known to have PALN enlargement, 
while 74 patients did not have PALN enlargement. 
Baseline characteristics of subjects can be found 
on Table 1.
56 Kusuma, Matondang, Nuranna, et al
Indones J
Obstet Gynecol
Table 1. Baseline Characteristics of Subjects
Characteristics N = 78
Age
First sexual intercourse age
  < 20 
























242 (18 – 1.460)
In order to determine the differences between 
study groups, bivariate analysis between groups 
was done. Result of bivariate analysis in this study 
can be found in Table 2.
In order to compare overall survival rate of 
patients, 1 year survival analysis using Kaplan-
Meier was done in this study. The Kaplan-Meier 
graph for this study can be found on fi gure 1.
It was known from the Kaplan Meier 
analysis that the median survival days for PALN 
enlargement group was 201 days, while median 
survival days for PALN negative group was 293 
days. However, the result was not statistically 
signifi cant (p = 0.072).
DISCUSSION
In this study, 78 research subjects fi tting the 
inclusion and exclusion criteria of the study were 
successfully followed up until the end of the study 
period. On these subjects, the average age was 
50.51 years (standard deviation 8.493 years). The 
mean age obtained in this study is higher than 
the average age of diagnosis of cervical cancer 
in both developed countries such as the United 
States (47 years) and in developing countries 
such as South Africa (40-49 years old). Previous 
studies have shown that older women tend to be 
diagnosed with more advanced cervical cancer 
while also having a higher mortality rate than 
younger patients.9,10
Cancer differentiation was generally poor in 
the study subjects (73.6%). The result is reasonable 
considering the inclusion criteria in this study 
were patients who have been diagnosed with 
advanced cervical cancer, thus having worse 
differentiation. However, the percentage of poor 
differentiation patient is higher than a similar 
study conducted in cervical cancer patients with 
paraaortic lymph node involvement in 2015 in 
Belgium which had 33% subjects having poor 
mass differentiation.11 Another study in Korea 
only had 1% research subjects who had poor 
cancer differentiation.12 In enlarged paraaortic 
lymph nodes group, it was found that 100% 
subjects had poor mass differentiation (p <0.001, 
RR = 3.89 CI95% 2.65-4.07).
In this study, only 4 people (5.1%) of 76 
study subjects experienced enlargement of the 
paraaortic lymph nodes. In the analysis between 
paraaortic lymph node enlargement and 
radiotherapy response, a signifi cant relationship 
was found (p = 0.02, RR = 2.13, CI95% 1.12 - 
4.07). In addition, the median survival of 1 year 
Figure 1. Kaplan-Meier Graph between Study Groups
Table 2. Result of Bivariate Analysis
Age
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for subjects with enlargement of the paraaortic 
lymph nodes was 201 days, while 1 year survival 
for subjects without enlarged lymph nodes was 
293 days. The P value was 0.072, meaning that 
there were no statistically signifi cant differences of 
survival rate between the study groups. Although 
data obtained was not statistically signifi cant, the 
median survival of patients obtained was judged 
to be clinically meaningful. In a previous study 
conducted specifi cally on cervical cancer patients 
with enlarged paraaortic lymph nodes in 2001, it 
was found that the estimated survival at 2 years 
was 46% and 4 years survival was 29%.13
Various factors infl uence the survival of cervical 
cancer patients with lymph node involvement. 
Some risk factors beyond lymph node involvement 
that have been proven to affect survival are 
ethnicity, tumor size, treatment performed, 
age, and nutritional status.3. A large amount of 
attempts have been made to improve overall 
survival in cervical cancer patients with enlarged 
paraaortic lymph nodes. Previous study assessed 
that the survival of cervical cancer patients with 
enlarged paraaortic lymph nodes that carried out 
radiotherapy extension until the paraaortic lymph 
nodes is similar compared to patients undergoing 
standard radiotherapy, despite having a much 
lower incidence of distant metastasis14. Another 
attempt to perform paraaortic lymphadenectomy 
before chemoradiotherapy in late cervical cancer 
is considered effective to improve survival 
only in patients who have not had an enlarged 
paraaortic lymph node. However, it has little to 
no difference in patients with enlarged paraaortic 
lymph nodes 15.
CONCLUSIONS
Patients with PALN enlargement have increased 
risk of having negative radiotherapy outcome 
(p < 0.05). There were no differences in 1 year 
survival between patients with advanced cervical 
cancer with enlargement PALN.
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